Literature DB >> 19053149

Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Shraddha Kumari1, Mukesh Samant, Prashant Khare, Pragya Misra, Sujoy Dutta, Bala Krishna Kolli, Sharad Sharma, Kwang Poo Chang, Anuradha Dube.   

Abstract

Leishmania, naturally residing in the phagolysosomes of macrophages, is a suitable carrier for vaccine delivery. Genetic complementation of these trypanosomatid protozoa to partially rectify their defective heme-biosynthesis renders them inducible with delta-aminolevulinate to develop porphyria for selective photolysis, leaving infected host cells unscathed. Delivery of released "vaccines" to antigen-presenting cells is thus expected to enhance immune response, while their self-destruction presents added advantages of safety. Such suicidal L. amazonensis was found to confer immunoprophylaxis and immunotherapy on hamsters against L. donovani. Neither heat-killed nor live parasites without suicidal induction were effective. Photodynamic vaccination of hamsters with the suicidal mutants reduced the parasite loads by 99% and suppressed the development of disease. These suppressions were accompanied by an increase in Leishmania-specific delayed-type hypersensitivity and lymphoproliferation as well as in the levels of splenic iNOS, IFN-gamma, and IL-12 expressions and of Leishmania-specific IgG2 in the serum. Moreover, a single intravenous administration of T cells from vaccinated hamsters was shown to confer on naïve animals an effective cellular immunity against L. donovani challenges. The absence of lesion development at vaccination sites and parasites in the draining lymphnodes, spleen and liver further indicates that the suicidal mutants provide a safe platform for vaccine delivery against experimental visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19053149      PMCID: PMC5056643          DOI: 10.1002/eji.200838389

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  56 in total

1.  Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation.

Authors:  I Vouldoukis; P A Bécherel; V Riveros-Moreno; M Arock; O da Silva; P Debré; D Mazier; M D Mossalayi
Journal:  Eur J Immunol       Date:  1997-04       Impact factor: 5.532

2.  Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

Authors:  R X Armijos; M M Weigel; M Calvopina; A Hidalgo; W Cevallos; J Correa
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

3.  Towards a strategy of universally efficacious vaccination against pathogens uniquely susceptible to cell-mediated attack.

Authors:  P A Bretscher; J N Menon; O Ogunremi
Journal:  J Biotechnol       Date:  1996-01-26       Impact factor: 3.307

4.  Photodynamic sensitization of Leishmania amazonensis in both extracellular and intracellular stages with aluminum phthalocyanine chloride for photolysis in vitro.

Authors:  Sujoy Dutta; Debalina Ray; Bala K Kolli; Kwang-Poo Chang
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 5.  Genetically modified live attenuated parasites as vaccines for leishmaniasis.

Authors:  Angamuthu Selvapandiyan; Robert Duncan; Alain Debrabant; Nancy Lee; G Sreenivas; Poonam Salotra; Hira L Nakhasi
Journal:  Indian J Med Res       Date:  2006-03       Impact factor: 2.375

Review 6.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 7.  The present and future of vaccination for cutaneous leishmaniasis.

Authors:  C L Greenblatt
Journal:  Prog Clin Biol Res       Date:  1980

8.  Splenic cytokine responses in Indian kala-azar before and after treatment.

Authors:  R T Kenney; D L Sacks; A A Gam; H W Murray; S Sundar
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

9.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts.

Authors:  Gerald F Späth; L A Garraway; Salvatore J Turco; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

View more
  14 in total

1.  Delta-aminolevulinate-induced host-parasite porphyric disparity for selective photolysis of transgenic Leishmania in the phagolysosomes of mononuclear phagocytes: a potential novel platform for vaccine delivery.

Authors:  Sujoy Dutta; Celia Chang; Bala Krishna Kolli; Shigeru Sassa; Malik Yousef; Michael Showe; Louise Showe; Kwang-Poo Chang
Journal:  Eukaryot Cell       Date:  2012-02-03

2.  Combinational sensitization of Leishmania with uroporphyrin and aluminum phthalocyanine synergistically enhances their photodynamic inactivation in vitro and in vivo.

Authors:  Sujoy Dutta; Kayoko Waki; Kwang Poo Chang
Journal:  Photochem Photobiol       Date:  2012-01-25       Impact factor: 3.421

3.  Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance.

Authors:  Rati Tandon; Sharat Chandra; Rajendra Kumar Baharia; Sanchita Das; Pragya Misra; Awanish Kumar; Mohammad Imran Siddiqi; Shyam Sundar; Anuradha Dube
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

4.  Aminophthalocyanine-Mediated Photodynamic Inactivation of Leishmania tropica.

Authors:  Ahmed Al-Qahtani; Saad Alkahtani; Bala Kolli; Pankaj Tripathi; Sujoy Dutta; Abdullah A Al-Kahtane; Xiong-Jie Jiang; Dennis K P Ng; Kwang Poo Chang
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

5.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

6.  Intracellular targeting specificity of novel phthalocyanines assessed in a host-parasite model for developing potential photodynamic medicine.

Authors:  Sujoy Dutta; Benson G Ongarora; Hairong Li; Maria da Graca H Vicente; Bala K Kolli; Kwang Poo Chang
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

Review 7.  New "light" for one-world approach toward safe and effective control of animal diseases and insect vectors from leishmaniac perspectives.

Authors:  Kwang Poo Chang; Bala K Kolli
Journal:  Parasit Vectors       Date:  2016-07-13       Impact factor: 3.876

8.  Photodynamic Vaccination of BALB/c Mice for Prophylaxis of Cutaneous Leishmaniasis Caused by Leishmania amazonensis.

Authors:  Sayonara M Viana; Fabiana S Celes; Laura Ramirez; Bala Kolli; Dennis K P Ng; Kwang P Chang; Camila I de Oliveira
Journal:  Front Microbiol       Date:  2018-02-06       Impact factor: 5.640

9.  Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani.

Authors:  Sumit Joshi; Narendra Kumar Yadav; Keerti Rawat; Vikash Kumar; Rafat Ali; Amogh Anant Sahasrabuddhe; Mohammad Imran Siddiqi; Wahajul Haq; Shyam Sundar; Anuradha Dube
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

Review 10.  Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.

Authors:  Sumit Joshi; Keerti Rawat; Narendra Kumar Yadav; Vikash Kumar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  Front Immunol       Date:  2014-08-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.